VKTX on Nasdaq

Viking Therapeutics

American biotechnology company based in San Diego, incorporated in Delaware.¹

Price unavailable

Last updated Oct 18, 2026.

Overview

2012Founded¹

Compare with another stock.

TickerVKTX on Nasdaq¹
Industrybiotechnology industry¹
HeadquartersSan Diego¹
Websitewww.vikingtherapeutics.com
Incorporated inDE³
Business address9920 Pacific Heights Blvd, Suite 500, San Diego, Ca³
Filer categoryLarge accelerated filer³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-56.3%Return on equity⁴

Financial statements

Revenue⁵⁶⁷⁸⁴$0 in 2025

Operating income⁵⁶⁷⁸⁴-$393.3M in 2025+1103% since 2019

Net income⁵⁶⁷⁸⁴-$359.6M in 2025+1295% since 2019

Every line of the income statement as filed: the last 3 fiscal years, latest first.⁴

Period ending	2025-12-31	2024-12-31	2023-12-31
Revenues	$0	$0	$0
Research and development	$345.0M	$101.6M	$63.8M
General and administrative	$48.4M	$49.3M	$37.0M
Total operating expenses	$393.3M	$150.9M	$100.8M
Loss from operations	-$393.3M	-$150.9M	-$100.8M
Amortization of financing costs	-$56.0K	-$94.0K	-$88.0K
Interest income, net	$33.7M	$40.9M	$15.0M
Realized gain on investments, net	$55.0K	$112.0K	$0
Total other income, net	$33.7M	$41.0M	$14.9M
Net loss	-$359.6M	-$110.0M	-$85.9M
Unrealized gain (loss) on securities	$1.1M	-$173.0K	$742.0K
Foreign currency translation gain (loss)	$47.0K	-$226.0K	-$29.0K
Comprehensive loss	-$358.5M	-$110.4M	-$85.2M
Basic net loss per common share	-$3.19	-$1.01	-$0.91
Weighted-average shares used to compute basic net loss per share	112.7M shares	109.0M shares	94.3M shares
Diluted net loss per common share	-$3.19	-$1.01	-$0.91
Weighted-average shares used to compute diluted net loss per share	112.7M shares	109.0M shares	94.3M shares

Total assets⁵⁶¹¹⁷⁸⁴$715.7M in 2025+152% since 2019

Total liabilities⁵⁶¹¹⁷⁸⁴$76.7M in 2025+974% since 2019

Shareholders’ equity⁵⁶¹¹⁷⁸⁴$639.1M in 2025+131% since 2019

Cash⁵⁶¹¹⁷⁸⁴$165.8M in 2025+1879% since 2019

Every line of the balance sheet as filed: the last 2 fiscal years (annual) or 2 quarters (quarterly), latest first.⁴

Period ending	2025-12-31	2024-12-31
Cash and cash equivalents	$165.8M	$26.7M
Short-term investments available for sale	$539.9M	$875.9M
Prepaid clinical trial and preclinical study costs	$8.1M	$3.5M
Prepaid expenses and other current assets	$1.8M	$1.1M
Total current assets	$715.6M	$907.2M
Right-of-use assets	$85.0K	$1.0M
Deferred financing costs	$0	$56.0K
Deposits	$46.0K	$46.0K
Total assets	$715.7M	$908.3M
Accounts payable	$53.3M	$9.8M
Other accrued liabilities	$23.3M	$17.1M
Lease liability, current	$137.0K	$489.0K
Total current liabilities	$76.7M	$27.4M
Lease liability, net of current portion	$0	$630.0K
Total long-term liabilities	$0	$630.0K
Total liabilities	$76.7M	$28.0M
Common stock, $0.00001 par value: 300,000,000 shares authorized at December 31, 2025 and December 31, 2024; 114,793,067 shares issued and outstanding at December 31, 2025 and 111,573,519 shares issued and outstanding at December 31, 2024	$1.0K	$1.0K
Treasury stock at cost, no shares at December 31, 2025 and December 31, 2024	$0	$0
Additional paid-in capital	$1.5B	$1.4B
Accumulated deficit	-$847.5M	-$487.9M
Accumulated other comprehensive loss	$378.0K	-$788.0K
Total stockholders equity	$639.1M	$880.3M
Total liabilities and stockholders equity	$715.7M	$908.3M
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10.0M shares	10.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300.0M shares	300.0M shares
Common stock, shares issued	114.8M shares	111.6M shares
Common stock, shares outstanding	114.8M shares	111.6M shares
Treasury stock, shares	0 shares	0 shares

Period ending	2025-12-31	2024-12-31
Cash and cash equivalents	$165.8M	$26.7M
Short-term investments available for sale	$539.9M	$875.9M
Prepaid clinical trial and preclinical study costs	$8.1M	$3.5M
Prepaid expenses and other current assets	$1.8M	$1.1M
Total current assets	$715.6M	$907.2M
Right-of-use assets	$85.0K	$1.0M
Deferred financing costs	$0	$56.0K
Deposits	$46.0K	$46.0K
Total assets	$715.7M	$908.3M
Accounts payable	$53.3M	$9.8M
Other accrued liabilities	$23.3M	$17.1M
Lease liability, current	$137.0K	$489.0K
Total current liabilities	$76.7M	$27.4M
Lease liability, net of current portion	$0	$630.0K
Total long-term liabilities	$0	$630.0K
Total liabilities	$76.7M	$28.0M
Common stock, $0.00001 par value: 300,000,000 shares authorized at December 31, 2025 and December 31, 2024; 114,793,067 shares issued and outstanding at December 31, 2025 and 111,573,519 shares issued and outstanding at December 31, 2024	$1.0K	$1.0K
Treasury stock at cost, no shares at December 31, 2025 and December 31, 2024	$0	$0
Additional paid-in capital	$1.5B	$1.4B
Accumulated deficit	-$847.5M	-$487.9M
Accumulated other comprehensive loss	$378.0K	-$788.0K
Total stockholders equity	$639.1M	$880.3M
Total liabilities and stockholders equity	$715.7M	$908.3M
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10.0M shares	10.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300.0M shares	300.0M shares
Common stock, shares issued	114.8M shares	111.6M shares
Common stock, shares outstanding	114.8M shares	111.6M shares
Treasury stock, shares	0 shares	0 shares

Cash from operations⁵⁶⁷⁸⁴-$278.7M in 2025+1026% since 2019

Every line of the cash flow as filed: the last 3 fiscal years, latest first.⁴

Period ending	2025-12-31	2024-12-31	2023-12-31
Net loss	-$359.6M	-$110.0M	-$85.9M
(Accretion) amortization of investment premiums	-$9.3M	-$17.3M	-$8.2M
Amortization of financing costs	$56.0K	$94.0K	$88.0K
Stock-based compensation	$40.8M	$29.7M	$16.8M
Amortization of right-of-use assets	$431.0K	$346.0K	$292.0K
Realized gain on investment	-$55.0K	-$112.0K	$0
Interest expense related to operating lease liability	$10.0K	$38.0K	$43.0K
Prepaid expenses and other current assets	-$5.2M	$446.0K	$6.4M
Accrued interest, net of interest receivable on maturity of investments	$5.1M	$1.2M	$321.0K
Accounts payable	$43.4M	$2.3M	-$1.0M
Accrued expenses	$6.2M	$5.8M	-$1.8M
Lease liability	-$505.0K	-$402.0K	-$347.0K
Net cash used in operating activities	-$278.7M	-$87.8M	-$73.4M
Purchases of investments	-$418.0M	-$1.1B	-$478.3M
Proceeds from sales and maturities of investments	$759.4M	$560.0M	$299.2M
Net cash (used in) provided by investing activities	$341.4M	-$553.4M	-$179.1M
Public offering, net of offering costs	$0	$597.1M	$269.8M
Value of shares withheld related to employee tax withholding	$0	-$42.1M	-$7.1M
Proceeds from warrant and option exercises and stock issuances under employee stock purchase plan	$2.5M	$10.8M	$6.8M
ATM offering, net of fees	$73.9M	$46.7M	$2.0M
Net cash provided by financing activities	$76.4M	$612.5M	$271.4M
Net (decrease) increase in cash and cash equivalents	$139.1M	-$28.7M	$18.9M
Effect of exchange rate changes on cash	-$8.0K	-$148.0K	-$30.0K
Unpaid deferred public offering and other financing costs	$50.0K	$50.0K	$50.0K
Right-of-use asset obtained in exchange for lease obligation	$0	$223.0K	$0

Compare Viking Therapeutics with another company

Leadership

Who has led Viking Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief executive

Brian Lian2015–now

President

Brian Lian2015–now

Chief financial officer

Chief operating officer

201520202025

Chief executive officerBrian Lian Apr 28, 2015 to now¹²
PresidentBrian Lian Apr 28, 2015 to now¹²
Chief financial officerGreg Zante Jan 6, 2021 to now¹³
Chief financial officerMichael Morneau Apr 28, 2015 to Jan 23, 2018¹⁴
Chief operating officerMarianna Mancini Jan 6, 2021 to now¹⁵
Chief operating officerMichael Dinerman Apr 28, 2015 to May 6, 2015¹⁶

Board members and other officers (12)

Chief Commercial OfficerNeil William Aubuchon Jan 26, 2026 to now¹⁷
Chief Medical OfficerHubert C. Chen Jun 3, 2026 to now¹⁸
VP, Finance and AdministrationMichael Morneau May 8, 2018 to Jan 19, 2021¹⁹
Chief Development OfficerHiroko Masamune Jul 3, 2018 to Jan 3, 2019²⁰
Chief Medical OfficerRochelle Hanley Apr 28, 2015 to May 5, 2016²¹
Board memberDorothy Elizabeth Kelly-Gemmell Aug 7, 2026 to now²²
Board memberSarah Kathryn Rouan Jul 2, 2019 to now²³
Board memberCharles A. Rowland Jr. Jul 5, 2017 to now²⁴
Board memberBrian Lian Apr 28, 2015 to now¹²
Board memberJ. Matthew Singleton Apr 28, 2015 to now²⁵
Board memberLawson Macartney Apr 28, 2015 to now²⁶
Board memberMatthew W. Foehr Apr 28, 2015 to now²⁷

Timeline

Apr 28, 2015New chief executive Brian Lian becomes CEO¹²
2012Founded Founded¹

Filings

292 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 41 major events, 106 insider forms, 28 large holders, 97 other. The latest 20:

Sep 28, 20268-K EDGAR
Sep 25, 2026424B5 EDGAR
Sep 25, 2026424B5 EDGAR
Sep 24, 2026FWP FREE WRITING PROSPECTUS EDGAR
Sep 24, 2026305B2 APPLICATION FOR DESIGNATION OF A NEW TRUSTEE EDGAR
Sep 23, 2026424B5 EDGAR
Sep 23, 2026424B5 EDGAR
Sep 22, 20268-K EDGAR
Aug 7, 20264 EDGAR
Aug 7, 20263 EDGAR
Jul 30, 2026S-3ASR EDGAR
Jul 29, 2026144 EDGAR
Jul 29, 2026144 EDGAR
Jul 29, 2026144 EDGAR
Jul 29, 20264 EDGAR
Jul 29, 20264 EDGAR
Jul 29, 20264 EDGAR
Jul 29, 202610-Q EDGAR
Jul 29, 20268-K EDGAR
Jun 3, 20264 EDGAR

The 292 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 28 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Fmr LLC	6,335,756	$247.2M	0.0%	+311,003
BlackRock, Inc.	6,189,649	$241.5M	0.0%	−690,641
State Street Corp	5,606,394	$218.7M	0.0%	+1,210,837
Vanguard Capital Management LLC	5,053,663	$197.1M	0.0%	+41,161
Vanguard Portfolio Management LLC	4,484,263	$174.9M	0.0%	+19,965
Two Sigma Investments, LP	3,937,414	$153.6M	0.1%	−494,728
Morgan Stanley	3,486,040	$136.0M	0.0%	+472,112
Ameriprise Financial Inc	2,156,083	$84.1M	0.0%	+477,338
Geode Capital Management, LLC	2,097,981	$81.9M	0.0%	+15,914
American Century Companies Inc	1,816,050	$70.8M	0.0%	−262,527
D. E. Shaw & Co., Inc.	1,605,994	$62.6M	0.0%	−70,719
Bnp Paribas Financial Markets	981,700	$38.3M	0.0%	+441,201
Citadel Advisors LLC	951,515	$37.1M	0.0%	−310,706
Goldman Sachs Group Inc	942,841	$36.8M	0.0%	−17,729
UBS Group AG	936,055	$36.5M	0.0%	−411,417
Jpmorgan Chase & Co	915,185	$36.4M	0.0%	+429,482
Jane Street Group, LLC	899,558	$35.1M	0.0%	+150,609
Susquehanna International Group, Llp	816,367	$31.8M	0.0%	+110,558
Raymond James Financial Inc	794,660	$31.0M	0.0%	−1,280,743
Vanguard Fiduciary Trust Co	732,047	$28.6M	0.0%	+21,635
Charles Schwab Investment Management Inc	730,690	$28.5M	0.0%	−5,775
Pictet Asset Management Holding SA	682,909	$26.6M	0.0%	−13,392
Vestal Point Capital, LP	680,000	$26.5M	0.6%	−234,147
Northern Trust Corp	626,719	$24.4M	0.0%	+53,443
Eversept Partners, LP	602,922	$23.5M	1.3%	+363,812

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataViking Therapeutics on Wikidata
2
SEC EDGARViking Therapeutics filings on SEC EDGAR
3
SEC EDGARViking Therapeutics filings on SEC EDGAR
4
SEC EDGARViking Therapeutics 10-K for fiscal 2025
5
SEC EDGARViking Therapeutics 10-K for fiscal 2019
6
SEC EDGARViking Therapeutics 10-K for fiscal 2020
7
SEC EDGARViking Therapeutics 10-K for fiscal 2021
8
SEC EDGARViking Therapeutics 10-K for fiscal 2022
9
SEC EDGARViking Therapeutics 10-Q for fiscal 2026
10
SEC EDGARViking Therapeutics 10-Q for fiscal 2026
11
SEC EDGARViking Therapeutics 10-K for fiscal 2021
12
SEC EDGARBrian Lian, Chief executive officer
13
SEC EDGARGreg Zante, Chief financial officer
14
SEC EDGARMichael Morneau, Chief financial officer
15
SEC EDGARMarianna Mancini, Chief operating officer
16
SEC EDGARMichael Dinerman, Chief operating officer
17
SEC EDGARNeil William Aubuchon, Chief Commercial Officer
18
SEC EDGARHubert C. Chen, Chief Medical Officer
19
SEC EDGARMichael Morneau, VP, Finance and Administration
20
SEC EDGARHiroko Masamune, Chief Development Officer
21
SEC EDGARRochelle Hanley, Chief Medical Officer
22
SEC EDGARDorothy Elizabeth Kelly-Gemmell, Board member
23
SEC EDGARSarah Kathryn Rouan, Board member
24
SEC EDGARCharles A. Rowland Jr., Board member
25
SEC EDGARJ. Matthew Singleton, Board member
26
SEC EDGARLawson Macartney, Board member
27
SEC EDGARMatthew W. Foehr, Board member